17.83

0.89% -0.16

After Hours: 17.85 0.02 +0.11%

Myriad Genetics Inc (MYGN)

Overview News Price History Option Chain Financials Why MYGN Down? Discussions Forecast Stock Split

Myriad Genetics Inc stock is traded at $17.83, with a volume of 1.85M. It is down -0.89% in the last 24 hours and down -32.64% over the past month. Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Previous Close:

$17.99

Open:

$17.63

24h Volume:

1.85M

Relative Volume:

2.62

Market Cap:

$1.62B

Revenue:

$802.20M

Net Income/Loss:

$-155.20M

P/E Ratio:

-5.3065

EPS:

-3.36

Net Cash Flow:

$-141.30M

1W Performance:

-18.81%

1M Performance:

-32.64%

6M Performance:

-8.42%

1Y Performance:

+4.76%

1-Day Range:

$16.87

$18.17

1-Week Range:

$16.86

$22.91

52-Week Range:

$15.99

$29.30

Myriad Genetics Inc Stock (MYGN) Company Profile

Name

Myriad Genetics Inc

Sector

Healthcare (1180)

Industry

Diagnostics & Research (57)

Phone

801-584-3600

Address

322 NORTH 2200 WEST, SALT LAKE CITY, UT

Employee

2,700

Twitter

@myriadgenetics

Next Earnings Date

2024-11-07

Latest SEC Filings

MYGN's Discussions on Twitter

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-21-23	Resumed	Piper Sandler	Neutral
Dec-19-23	Initiated	Wells Fargo	Equal Weight
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Jul-05-23	Resumed	JP Morgan	Underweight
May-23-23	Upgrade	Goldman	Sell → Buy
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform
Oct-06-22	Initiated	Stephens	Equal-Weight
Oct-15-21	Resumed	Cowen	Market Perform
Jun-15-21	Initiated	Raymond James	Mkt Perform
Jun-03-21	Initiated	Goldman	Sell
Sep-26-19	Downgrade	BofA/Merrill	Neutral → Underperform
Aug-14-19	Downgrade	Piper Jaffray	Overweight → Neutral
Aug-02-19	Upgrade	BofA/Merrill	Underperform → Neutral
Aug-01-19	Upgrade	Barclays	Underweight → Equal Weight
Jul-29-19	Downgrade	Needham	Strong Buy → Hold
Jul-09-19	Downgrade	Cowen	Outperform → Market Perform
Mar-12-19	Reiterated	Needham	Strong Buy
Jan-03-19	Initiated	Needham	Strong Buy
Nov-30-18	Upgrade	Goldman	Sell → Neutral
Oct-10-18	Upgrade	Piper Jaffray	Neutral → Overweight
Jul-11-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-21-18	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jan-29-18	Initiated	Goldman	Sell
Jan-22-18	Reiterated	Barclays	Equal Weight
Jan-05-18	Initiated	BTIG Research	Buy
Oct-02-17	Resumed	Leerink Partners	Mkt Perform
Aug-09-17	Reiterated	Barclays	Equal Weight
Feb-08-17	Upgrade	Ladenburg Thalmann	Sell → Neutral
Jan-18-17	Initiated	Deutsche Bank	Sell
Oct-10-16	Downgrade	Ladenburg Thalmann	Neutral → Sell

View All

Myriad Genetics Inc Stock (MYGN) Latest News

06:36 AM

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out - AccessWire

06:36 AM

03:36 AM

Myriad Genetics (NASDAQ:MYGN) Shares Down 4.6%Here's Why - MarketBeat

03:36 AM

11:42 AM